Literature DB >> 32910863

Early predictive blood markers of hemorrhagic stroke - influence of cytoflavin therapy.

Ekaterina V Silina1, Sofia A Rumyantceva2, Victor A Stupin3, Vladimir A Parfenov2, Sergey B Bolevich1.   

Abstract

Examination of the patterns of free-radical processes (FRP) and changes of the early screening markers to predict the course of hemorrhagic stroke (HS) and applied pathophysiologically based therapy can be of great practical importance. This study aimed to determine early changes in the parameters of oxidative stress and routine biochemistry blood tests in patients with HS and to assess their relationship with clinical outcome. The effects of early applied cytoflavin were also investigated. The prospective study included 151 patients with HS. Forty-eight percent of patients in the standard conservative therapy were given cytoflavin antioxidant energy therapy from the first day of hospitalization. The neurological status, neuroimaging, biochemical blood tests and FRP were assessed on days 1, 5, 10, and 20 of hospitalization. In patients with HS, an imbalance of all stages of FRP was detected proportionately to the severity of HS. The malondialdehyde concentration above 5.3 μmol/L, the number of leukocytes above 15 800, glucose above 11.9 mmol/L, lactate dehydrogenase above 574 IU/L, and lactate above 2.5 mmol/L, detected on the first day, predetermined a high risk of death. Additional cytoflavin treatment allowed stabilizing the clinical laboratory picture of HS, improved the treatment results, and reduced hospital mortality rate.

Entities:  

Keywords:  AVC hémorragique; cytoflavin; cytoflavine; hemorrhagic stroke; lethality; létalité; marqueurs pronostiques; oxidative stress; prognostic markers; stress oxydatif

Year:  2020        PMID: 32910863     DOI: 10.1139/cjpp-2020-0277

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

1.  Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER).

Authors:  Tatiana Kharitonova; Yury G Shvarts; Andrey F Verbovoy; Natalia S Orlova; Valentina P Puzyreva; Igor A Strokov
Journal:  BMJ Open Diabetes Res Care       Date:  2022-06

2.  Oxidative Stress and Free Radical Processes in Tumor and Non-Tumor Obstructive Jaundice: Influence of Disease Duration, Severity and Surgical Treatment on Outcomes.

Authors:  Ekaterina Vladimirovna Silina; Victor Alexandrovich Stupin; Igor Sergeevich Abramov; Sergey Brankovich Bolevich; Gouri Deshpande; Raghu Ram Achar; Tatiana Georgievna Sinelnikova
Journal:  Pathophysiology       Date:  2022-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.